Modeled speed is a PK→PD construct describing how absorption rate, absorption timing, solubility, gastric emptying, distribution loading, distribution geometry, and clearance shape the rising-phase geometry for sildenafil and avanafil. “Speed” refers strictly to modeled PK→PD behavior, not real-world performance. Absorption rate determines rising-phase steepness, absorption timing determines temporal alignment, solubility determines dissolution-driven availability, and gastric emptying determines input arrival. Distribution loading determines early central availability, while distribution geometry and clearance geometry determine how rapidly material spreads or is removed. First-pass metabolism determines systemic fraction. These PK parameters generate concentration-time trajectories. PD interpretation then determines modeled onset and peak geometry: threshold placement defines the onset boundary, binding sensitivity transforms concentration differences, coupling geometry shapes downstream transitions, and PD noise bands add interpretation variability. This framework separates PK curve generation from PD transformation and keeps speed as a geometric modeling coordinate rather than an observed outcome. Link to speed overview.
Modeled onset comparison begins with the geometry of the concentration-time trajectory. Faster modeled absorption steepens the rising phase, earlier absorption timing shifts the rising phase leftward, solubility determines dissolution-driven availability, and gastric-emptying variability shifts input arrival. Distribution loading determines early central-compartment concentration. Distribution geometry determines how rapidly absorbed material spreads across compartments. Clearance geometry determines removal dynamics. First-pass metabolism determines systemic fraction, while concentration-dependent clearance can alter curvature across the trajectory. These mechanisms interact: faster modeled absorption may be offset by faster modeled clearance, while earlier modeled timing may be offset by broader distribution geometry. Under onset modeling, PK geometry supplies the input curve that PD parameters transform. Threshold placement determines where the curve enters the modeled onset region, while binding sensitivity and coupling geometry reshape that transition. Tmax and Cmax describe peak timing and amplitude generated by the same PK trajectory. Link to onset time and peak time.
Modeled peak, Tmax, and Cmax comparison depends on how the PK trajectory is transformed by PD geometry. Threshold placement determines where the concentration curve intersects the modeled onset coordinate. Binding sensitivity determines how concentration differences are transformed into binding differences; higher modeled sensitivity can expand separation, while lower sensitivity can compress it. Coupling geometry determines how binding is mapped into downstream PD signals; shallow slopes broaden transitions, while steep slopes compress them. PD noise bands widen or narrow interpretation regions around the modeled signal. Because sildenafil and avanafil can be represented by differing parameter sets for absorption rate, solubility, gastric emptying, distribution loading, distribution geometry, and Tmax/Cmax geometry, the resulting PK→PD mapping can expand or compress modeled speed differences. Peak geometry therefore reflects both concentration trajectory and response transformation, rather than a single PK parameter. The framework keeps onset, peak, Tmax, and Cmax distinct while relating them through one modeled temporal system. Link to Cmax speed.
Modeled PK speed geometry is generated by the timing and shape of systemic input and subsequent disposition. Absorption rate controls the steepness of concentration increase, while absorption timing positions that increase along the modeled time axis. Solubility influences the dissolution component of input, and gastric emptying determines when material reaches the absorptive environment. Absorption window width determines whether input is concentrated or distributed across time. Distribution loading controls early central availability, while distribution geometry determines compartmental exchange and redistribution timing. First-pass metabolism modifies the systemic fraction entering the modeled circulation. Bioavailability scales the available systemic input, whereas clearance geometry determines how quickly concentration declines. Concentration-dependent clearance can introduce curvature that changes the relationship between input and later exposure. Together, these parameters define the PK trajectory from initial rise through peak and decline. Speed comparison therefore examines trajectory geometry rather than assigning a real-world performance property to either compound. Link to absorption rate.
PK variability in this framework means variation across modeled parameter sets, not observed clinical variability. Changes in absorption timing, absorption rate, gastric emptying, solubility, absorption window width, distribution loading, distribution geometry, redistribution timing, first-pass metabolism, bioavailability, and clearance geometry can shift, steepen, flatten, widen, or narrow the concentration-time trajectory. One parameter may accelerate a modeled rising phase while another broadens the input window or increases modeled removal, producing a different composite curve. Consequently, a single speed coordinate is insufficient to represent every trajectory. Modeled speed windows can instead be visualized as regions bounded by alternative parameter combinations. Tmax geometry identifies the location of the modeled concentration maximum, while Cmax geometry identifies its amplitude. These coordinates can move independently when absorption and disposition parameters change. Distribution geometry can also separate early and later concentration regions without requiring a change in the initial input rate. Link to distribution speed.
| PK Domain | Speed Interaction | Link |
|---|---|---|
| Absorption Rate | Steeper rising phase. | absorption rate |
| Distribution Geometry | Compartmental spread. | distribution speed |
| Clearance | Removal geometry. | elimination speed |
PD interpretation begins with the modeled concentration trajectory and applies explicit response geometry. Threshold placement establishes the concentration boundary associated with the onset coordinate, so moving that boundary changes the modeled crossing time without requiring a change in PK input. Binding sensitivity controls how concentration differences are translated into modeled binding differences. Coupling geometry maps binding into a downstream PD signal, with slope and curvature determining transition shape. PD noise bands represent modeled spread around the transformed signal and can widen the region assigned to a particular coordinate. These parameters therefore modify how the same PK trajectory is represented in onset and peak space. A lower threshold can produce an earlier modeled crossing, while a higher threshold can produce a later crossing; neither constitutes a real-world timing prediction. Binding sensitivity can expand or compress modeled separation between trajectories. Coupling geometry can similarly reshape peak transitions. Link to pd speed.
PK and PD geometry interact sequentially but are analytically distinct. PK parameters generate concentration trajectories through absorption, distribution, metabolism, and clearance, while PD parameters transform those trajectories into modeled signal coordinates. Binding sensitivity determines how strongly concentration differences are represented at the binding stage. Coupling geometry then determines how binding differences propagate into the modeled downstream signal. Steeper coupling can compress a transition into a narrower concentration region, whereas shallower coupling can broaden it. PD noise bands add a modeled spread around these transformed trajectories, allowing comparison of overlapping or separated regions without treating the result as an observed outcome. PK speed remains anchored to trajectory geometry, while PD speed describes the transformation of that geometry into onset or peak coordinates. The combined framework therefore distinguishes PK-generated differences from PD-generated amplification or compression. Link to pk speed.
| PD Domain | Speed Effect | Link |
|---|---|---|
| Threshold Placement | Earlier/later onset. | onset time |
| Binding Sensitivity | Amplification/compression. | onset variability comparison |
| Coupling Geometry | Slope-driven shaping. | peak variability comparison |
Modeled speed differences arise from the combined geometry of drug input, distribution, and removal. Absorption rate controls how sharply concentration rises, while absorption timing determines where that rise appears on the modeled time axis. Gastric emptying and solubility shape the timing and extent of input, and absorption window width determines whether input is concentrated or spread across time. Distribution loading and distribution geometry influence early central availability and subsequent compartmental exchange. First-pass metabolism and bioavailability alter the systemic input fraction. Clearance geometry determines how the trajectory declines, while concentration-dependent clearance can modify curvature. These parameters interact rather than acting independently, so modeled speed is a composite trajectory property. PD parameters then transform that PK trajectory through threshold placement, binding sensitivity, coupling geometry, and noise bands. The resulting onset or peak coordinates therefore describe model behavior generated by specified parameter combinations, not real-world speed, effectiveness, or patient outcomes.
The principal PK mechanisms are absorption timing, absorption rate, gastric emptying, solubility, absorption window width, distribution loading, distribution geometry, redistribution timing, first-pass metabolism, bioavailability, and clearance geometry. Absorption timing determines when systemic input begins to contribute to the modeled concentration curve, whereas absorption rate determines the steepness of the rising phase. Gastric emptying can shift input arrival, and solubility can alter dissolution-related availability. A narrow absorption window concentrates input temporally, while a broader window distributes it across time. Distribution loading and compartmental geometry influence how rapidly central concentration changes after absorption. Redistribution timing can reshape later portions of the trajectory. First-pass metabolism and bioavailability determine the systemic fraction represented by the model. Clearance geometry governs decline, and concentration-dependent clearance can alter that decline nonlinearly. Their combined effects determine modeled Tmax, Cmax, and trajectory shape, without establishing a real-world onset prediction or performance conclusion.
PD mechanisms determine how a modeled concentration trajectory is translated into a modeled response coordinate. Threshold placement establishes the concentration boundary associated with the onset coordinate, so moving that boundary changes the modeled crossing time without necessarily changing the PK curve. Binding sensitivity controls how concentration differences are represented as binding differences. Coupling geometry maps binding into a downstream PD signal, with slope and curvature affecting transition shape. PD noise bands represent modeled uncertainty or spread around that transformation and can broaden the apparent coordinate region. These mechanisms operate after, or alongside, the PK trajectory generation step. Consequently, identical PK curves can produce different modeled onset or peak geometry under different PD parameterizations. Conversely, different PK curves can converge under a PD transformation that compresses their differences. The framework therefore treats onset and peak as PK→PD constructs produced by explicit model geometry, rather than as direct measurements of real-world performance or outcomes.
Sildenafil and avanafil can differ in modeled speed geometry when their parameter sets differ across absorption, distribution, metabolism, clearance, or PD transformation variables. A modeled difference in absorption rate changes rising-phase steepness, while a difference in absorption timing shifts the trajectory along the time axis. Solubility, gastric emptying, and absorption-window width can modify the timing and spread of systemic input. Distribution loading, distribution geometry, and redistribution timing reshape early and intermediate concentration regions. First-pass metabolism and bioavailability modify systemic exposure, while clearance geometry determines decline. These PK differences generate distinct modeled Tmax and Cmax coordinates. PD threshold placement can move the modeled onset crossing, binding sensitivity can expand or compress concentration separation, and coupling geometry can reshape downstream signal transitions. Thus, the modeled difference is not attributable to one universal speed parameter. It emerges from the interaction of multiple specified parameters within a PK→PD system, without implying a real-world speed ranking or outcome.
PK→PD mapping explains modeled speed differences by treating concentration-time geometry as the input to a response transformation. PK parameters first generate the trajectory: absorption timing and rate shape the rising phase; gastric emptying, solubility, and absorption-window width shape input timing; distribution parameters shape compartmental loading and exchange; and metabolism and clearance shape systemic persistence and decline. Tmax and Cmax emerge as geometric coordinates of that trajectory. PD parameters then transform concentration into a modeled signal. Threshold placement determines the crossing coordinate associated with onset, binding sensitivity determines the magnitude of concentration-to-binding transformation, and coupling geometry determines downstream signal shape. Noise bands represent modeled spread around the transformed trajectory. A change in any layer can therefore alter the apparent separation between sildenafil and avanafil within the model. The resulting geometry is a parameter-dependent representation of PK→PD behavior, not a prediction of real-world onset, effectiveness, or patient outcomes.